Plan of Action and Milestones Sample Clauses

Plan of Action and Milestones. (POA&M): The Contractor shall provide a Plan of Action and Milestones (POA&M) within the first 30 calendar days and then every 3 months thereafter for a total of 3. This POA&M shall include how and when the tasks within section 4 would be delivered. More specifically, details shall include, but not limited to, reduction (by number or % of tickets) of the issue tracking tool tickets (Bugs, Feature Requests, Tasks) for CXXI model and SITS improvements and enhancements, expansion/standardization of documentation, testing software development (functional tests, regression tests, verification tests, acceptance tests, comparison tests, deep-dive analysis), promptness of helpdesk –issue support, and upholding of configuration management. It shall also include how requirements will be gathered and user feedback would be incorporated into software development resolutions. Government will have 10 working days to approve the POA&M.
Sample 1
AutoNDA by SimpleDocs
Plan of Action and Milestones. (POA&M). The contractor will develop Plan of Action and Milestones (POA&M) outlining how Contractor will execute the deliverables contained in the contract and submit to COR for subsequent dissemination to the Functional Representative not later than 30 days after award.
Sample 1
Plan of Action and Milestones. (POA&M) (CRDL A005)
Sample 1
Plan of Action and Milestones. (POA&M) The Contractor shall develop a POA&M at the Contract Level/Summary and for each work area (WA) (CDRL A009). The POA&M shall be signed by the Contractor, Government Subject Matter Expert (SME), COR, and the Government Contracting Officer. The signed POA&M shall be provided electronically to the Contract Specialist, COR, ACOR, and the appropriate Government SME within twenty one (21) calendar days after Contract Performance Start, Exercise of Option, Award Term issuance, or modification which affect the Level of Effort (XXX) or Dollar Ceilings. While Contractor format is acceptable, with the COR’s approval, the following information shall appear, at a minimum, on each POA&M:
Sample 1
Plan of Action and Milestones. Xxxxxxx, LLP has drafted a Trust Agreement for establishment of the Trust. The draft was presented to the Commissioners at an April 18 worksession. The Commissioners had no recommended changes. Staff had additional changes clarifying some of the investment language in Article V, adding Article 3.4, which allows WSSC to provide administrative support to the Trustees, and changing the valuation year end in Article 1.1
Sample 1
Plan of Action and Milestones. Develop a plan of action and milestones for systems to document the planned remedial actions of the organization to correct weaknesses or deficiencies noted during the assessment of the controls and to reduce or eliminate known vulnerabilities in the system; and updating existing plans based on findings from control assessments, impact analyses, and continuous monitoring activities.
Sample 1
Plan of Action and Milestones. Xxxxxxx, LLP has drafted a Trust Agreement for establishment of the Trust. It is anticipated that the final Trust Agreement will be presented for Commission approval at the May Commission meeting. Once the Trust Agreement has been approved by the Commission, Trustees will need to be appointed, a Federal tax ID will be obtained, and the accounting records for the Trust will be established. Details: Attached is the most recent draft of the Trust Agreement. Certain sections of the Articles have been removed as a result of staff review. The numbering will be corrected after any Commissioner comments have been addressed. Additionally, there will be changes to consolidate the terms “Commission” and “Administrator” throughout the document, since they are the same entity for the purposes of the Trust. WASHINGTON SUBURBAN SANITARY COMMISSION RETIREE OTHER POST EMPLOYMENT BENEFITS TRUST EXECUTIVE SUMMARY Article I—Definitions and Construction Provides defined terms used throughout the Trust Agreement.
Sample 1
AutoNDA by SimpleDocs

Related to Plan of Action and Milestones

  • Defense of Actions In any case in which any such action is brought against any indemnified party, and it notifies an indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate therein, and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not (so long as it shall continue to have the right to defend, contest, litigate and settle the matter in question in accordance with this paragraph) be liable to such indemnified party hereunder for any legal or other expense subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation, supervision and monitoring (unless (i) such indemnified party reasonably objects to such assumption on the grounds that there may be defenses available to it which are different from or in addition to the defenses available to such indemnifying party, (ii) counsel to the indemnifying party has informed the indemnifying party that the joint representation of the indemnifying party and one or more indemnified parties could be inappropriate under applicable standards of professional conduct, or (iii) the indemnifying party shall have failed within a reasonable period of time to assume such defense and the indemnified party is or is reasonably likely to be prejudiced by such delay, in any such event the indemnified party shall be promptly reimbursed by the indemnifying party for the expenses incurred in connection with retaining separate legal counsel). An indemnifying party shall not be liable for any settlement of an action or claim effected without its consent (such consent not to be unreasonably withheld). The indemnifying party shall lose its right to defend, contest, litigate and settle a matter if it shall fail to diligently contest such matter (except to the extent settled in accordance with the next following sentence). No matter shall be settled by an indemnifying party without the consent of the indemnified party (which consent shall not be unreasonably withheld, it being understood that the indemnified party shall not be deemed to be unreasonable in withholding its consent if the proposed settlement imposes any obligation on the indemnified party).

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Limitation of Actions Any claim or cause of action by Borrower against Silicon, its directors, officers, employees, agents, accountants or attorneys, based upon, arising from, or relating to this Loan Agreement, or any other present or future document or agreement, or any other transaction contemplated hereby or thereby or relating hereto or thereto, or any other matter, cause or thing whatsoever, occurred, done, omitted or suffered to be done by Silicon, its directors, officers, employees, agents, accountants or attorneys, shall be barred unless asserted by Borrower by the commencement of an action or proceeding in a court of competent jurisdiction by the filing of a complaint within one year after the first act, occurrence or omission upon which such claim or cause of action, or any part thereof, is based, and the service of a summons and complaint on an officer of Silicon, or on any other person authorized to accept service on behalf of Silicon, within thirty (30) days thereafter. Borrower agrees that such one-year period is a reasonable and sufficient time for Borrower to investigate and act upon any such claim or cause of action. The one-year period provided herein shall not be waived, tolled, or extended except by the written consent of Silicon in its sole discretion. This provision shall survive any termination of this Loan Agreement or any other present or future agreement.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Litigation and Regulatory Cooperation During and after the Executive’s employment, the Executive shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company. The Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 7(f).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!